We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sareum Holdings plc (SAR) ORD GBP0.0125

Sell:27.00p Buy:29.00p 0 Change: No change
Market closed Prices as at close on 26 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:27.00p
Buy:29.00p
Change: No change
Market closed Prices as at close on 26 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:27.00p
Buy:29.00p
Change: No change
Market closed Prices as at close on 26 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.

Contact details

Address:
Unit 2A
Langford Arch, London Road, Pampisford
CAMBRIDGE
CB22 3FX
United Kingdom
Telephone:
+44 (01223) 497700
Website:
https://sareum.com/

Important dates

Future events
There are no future events available.
Past events
AGM 07 November 2024 07/11/24
Final results 29 October 2024 29/10/24
Drilling report 23 October 2024 23/10/24
Interim results 28 March 2024 28/03/24
AGM 14 December 2023 14/12/23

General stock information

EPIC:
SAR
ISIN:
GB00BMC3RJ87
Market cap:
£34.93 million
Shares in issue:
124.75 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Stephen Parker
    Executive Chairman of the Board
  • John Reader
    Founder, Chief Scientific Officer, Executive Director
  • Tim Mitchell
    Chief Operating Officer - Part-Time, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.